- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Antibody Production
- Protein Production
- Protein Characterization
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
Poster modified on 17/10/2023
Establishment of an Ultra High-Throughput Protein Production Platform (Ultra 96) for Early Stage in vitro Studies
Kai Jiang, Huishuai Li, Mengjie Lu, Chuanlong Tang, Xuejian Zhang, Ying Zhang, Zhengyang Zhao, Jun Zhou, Jiansheng Wu
WuXi Biologics, NO.240 Hedan Road, Pudong New District, Shanghai, China
In early stage drug discovery, numerous μg to mg scale high quality proteins need to be produced for in vitro functional studies and therapeutic evaluation, including antigens, monoclonal antibodies (mAb), bispecific antibodies (bsAbs) as well as other Fc-fusion proteins. Here we present how WuXi Biologics has created a powerful ultra HTP protein production platform (termed as “Ultra 96”) that can automatically produce proteins within 3 weeks with one step purification at 1~ 3mL expression scale by using 96 and 24 well DWP.
This scientific poster was originally presented during the Festival of Biologics 2023 conference
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.